yingweiwo
  1. Home
  2. Products
  3. Signaling Pathways
  4. Angiogenesis
  5. ALK

ALK

ALK

ALK, a member of the insulin receptor superfamily and a receptor tyrosine kinase, is primarily expressed in the brain and is thought to play a role in cognition and neuronal development. Adenosine triphosphate (ATP) and a gamma-phosphate group are transferred via ALK to a tyrosine residue on a substrate protein. As a result, it causes the tyrosine residues in its substrate proteins to phosphorylate. Different enzymes (kinases and phosphatases) catalyze the important protein reactions of phosphorylation and dephosphorylation, which are essential to many cellular processes.
ALK gene activation results from fusion with other oncogenes (NPM, EML4, TIM, etc.) or gene amplification, mutation, or protein overexpression and contributes to the development of several human cancers, including anaplastic large cell lymphoma, lung cancer, inflammatory myofibroblastic tumors, and neuroblastoma. ALK is a transmembrane tyrosine kinase receptor that dimerizes and then autophosphorylates the intracellular kinase domain in response to ligand binding to its extracellular domain. Specific inhibitors, like Crizotinib, Ceritinib, Alectinib, etc., have shown to be highly effective in treating ALK-positive non-small cell lung cancer in particular when it becomes activated in cancer.

ALK related products

Structure Cat No. Product Name CAS No. Product Description
(E)-Belizatinib V111536 (E)-Belizatinib 1388225-72-6 (E)-Belitazartinib ((E)-TSR-011) (compound 36) is the (E)-isomer of belitazartinib, a potent, selective, and orally effective anaplastic lymphoma kinase (ALK) inhibitor with an enzymatic IC50 of 0.005 μM and a cellular IC50 of 0.048 μM.
Alectinib-d8 (CH5424802-d8; RO5424802-d8; AF802-d8) V69256 Alectinib-d8 (CH5424802-d8; RO5424802-d8; AF802-d8) 1256585-15-5 Alectinib-d8 is the deuterated form of Alectinib.
ALK C1156Y Recombinant Human Active Protein Kinase V118347 ALK C1156Y Recombinant Human Active Protein Kinase Anaplastic lymphoma kinase (ALK) is a receptor tyrosine kinase in the insulin receptor superfamily.
ALK degrader 1 V118297 ALK degrader 1 ALK degrader 1 is a highly efficient hydrophobic label-based (HyT) degrader that degrades EML4-ALK (DC50 = 0.13 μM) via the ubiquitin-proteasome system.
ALK degrader 2 V119089 ALK degrader 2 ALK Degrader 2 is an orally effective ALK degrader that degrades EML4-ALK protein (DC50 = 8 nM) and nucleophosphoprotein (NPM)-ALK protein (DC50 = 102 nM).
ALK F1174L Recombinant Human Active Protein Kinase V118883 ALK F1174L Recombinant Human Active Protein Kinase Anaplastic lymphoma kinase (ALK) is a receptor tyrosine kinase in the insulin receptor superfamily.
ALK F1174S Recombinant Human Active Protein Kinase V119027 ALK F1174S Recombinant Human Active Protein Kinase Anaplastic lymphoma kinase (ALK) is a receptor tyrosine kinase in the insulin receptor superfamily.
ALK G1202R Recombinant Human Active Protein Kinase V118876 ALK G1202R Recombinant Human Active Protein Kinase Anaplastic lymphoma kinase (ALK) is a receptor tyrosine kinase in the insulin receptor superfamily.
ALK L1196M Recombinant Human Active Protein Kinase V118959 ALK L1196M Recombinant Human Active Protein Kinase Anaplastic lymphoma kinase (ALK) is a receptor tyrosine kinase in the insulin receptor superfamily.
ALK ligand-1 V119113 ALK ligand-1 2353496-79-2 ALK ligand-1 is an ALK ligand that can be used to synthesize PROTAC ALK degrader-4.
ALK ligand-Linker Conjugate 1 V119290 ALK ligand-Linker Conjugate 1 2796974-34-8 ALK ligand-linker conjugate 1 is an ALK ligand-linker conjugate that can be used to synthesize PROTAC ALK degrader-4.
ALK R1275Q Recombinant Human Active Protein Kinase V118918 ALK R1275Q Recombinant Human Active Protein Kinase Anaplastic lymphoma kinase (ALK) is a receptor tyrosine kinase in the insulin receptor superfamily.
ALK-IN-12 V69260 ALK-IN-12 1197958-53-4 ALK-IN-12 is a potent and orally bioactive ALK inhibitor (antagonist) with IC50 of 0.18 nM.
ALK-IN-13 V69264 ALK-IN-13 1197953-88-0 ALK-IN-13 is an ALK inhibitor from patent US20130225528A1, example 19.
ALK-IN-21 V69265 ALK-IN-21 2901889-01-6 ALK-IN-21 (Compound B10) is a potent ALK inhibitor (antagonist) with IC50s of 4.59 nM, 2.07 nM and 5.95 nM for ALKWT, ALKL1196M and ALKG1202R respectively.
ALK-IN-27 V69247 ALK-IN-27 2739866-40-9 ALK-IN-27 (compound 1) is a potent ALK inhibitor.
ALK-IN-27 TFA V87981 ALK-IN-27 TFA ALK-IN-27 TFA is the TFA salt form of ALK-IN-27.
ALK-IN-29 V94371 ALK-IN-29 ALK-IN-29 (compound 4c) has certain inhibitory effects on tyrosine protein kinases ALK, CDK2/CyclinE1, and FAK. Among them, the inhibitory effect on ALK kinase is the strongest, with an inhibition rate of 40.63% at a concentration of 10 μM. ALK-IN-29 can be used for anti-cancer research.
ALK-IN-33 V110378 ALK-IN-33 ALK-IN-33 (compound 8q) is an orally effective ALK inhibitor with an IC50 value of 1.61 nM.
ALK-IN-5 V69257 ALK-IN-5 2351929-66-1 ALK-IN-5 is a selective, brain barrier-permeable/penetrable (ALK) kinase inhibitor (antagonist) with IC50 of 2.9 nM.
Contact Us
Tel: 1-708-310-1919 Fax: 1-708-557-7486 Email: [email protected] Frequently Asked Questions
Subscribe to our E-newsletter
Name
E-mail

Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved

linkedin facebook
Contact Us
Home Product Cart Member